Pfizer Inc.

NYSE:PFE  
52.77
-1.28 (-2.37%)
5:00:57 PM EDT: $52.60 -0.17 (-0.32%)
Products

U.S. FDA Approves Pfizer’s Cibinqo For Adults With Moderate-To-Severe Atopic Dermatitis

Published: 01/14/2022 21:24 GMT
Pfizer Inc. (PFE) - U.S. FDA Approves Pfizer’s Cibinqo® (abrocitinib) for Adults With Moderate-to-severe Atopic Dermatitis.
Pfizer Inc - Cibinqo is Approved at Recommended Doses of 100 Mg and 200 Mg.